Induced pluripotent stem (iPS) cells: an up-to-the-minute review by Lau, Frank et al.
Induced pluripotent stem (iPS) cells: an up-to-the-minute review
Frank Lau
1, Tim Ahfeldt
1, Kenji Osafune
2,3, Hidenori Akustsu
4 and
Chad A Cowan
1*
Addresses:
1Stowers Medical Institute and Harvard Stem Cell Institute, Harvard University, Department of Stem Cell and Regenerative Biology,
185 Cambridge Street CPZN 4234, Boston, MA 02114, USA;
2Center for iPS Cell Research and Application (CiRA), Institute for Integrated
Cell-Material Sciences (iCeMS), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan;
3PRESTO, Yamanaka iPS Cell
Special Project, Japan Science and Technology Agency (JST), 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan;
4National Research Institute
for Child Health and Development, Department of Reproductive Biology, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan
*Corresponding author: Chad A Cowan (ccowan1@partners.org)
F1000 Biology Reports 2009, 1:84 (doi:10.3410/B1-84)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Biology/content/1/84
Abstract
Recent advances in nuclear reprogramming technology allow the transformation of terminally
differentiated, adult cells into induced pluripotent stem cells whose phenotype is indistinguishable
from that of embryonic stem cells. This leap forward enables the creation of patient-specific
pluripotent cell lines that carry disease genotypes. These cell lines could be used both as in vitro
models for the study of disease and as potential sources of material for cell replacement therapy.
Ultimately, a greater understanding of the process by which cellular identity is shaped and altered may
allow the generation of particular cell types for the treatment of degenerative disease.
Introduction and context
Development involves two distinct cellular processes:
division and differentiation. Division is the means by
which one cell gives rise to two daughter cells and is
indispensable for the growth of an organism and the
renewal of fully developed tissues. Differentiation refers
to the process by which a cell specializes to perform a
particular biological function in an adult. Differentiation
usually occurs through a combination of cell-cell
interactions, exposure to diffusible factors, and other
positional cues that ultimately alter gene expression,
conferring a specific cellular identity and function.
One of the more remarkable observations in the past
century is that differentiation is not a unidirectional
process. Instead, it can be turned back much like the
hands of a clock. This rewinding of the developmental
clock is termed nuclear reprogramming and is often
defined as the process whereby an adult somatic nucleus
has developmental potential restored to it [1]. There are
three ways that nuclear reprogramming has been
accomplished: (a) somatic cell nuclear transfer or
cloning, (b) cell fusion, and (c) factor-based reprogram-
ming to produce induced pluripotent stem (iPS) cells.
Here, we will discuss each approach with special
emphasis on the most recent advances in this field and
the challenges that lie ahead.
Somatic cell nuclear transfer, a procedure in which the
nucleus of an adult cell is injected into an unfertilized
egg whose chromosomes have been removed, has
demonstrated that the genome of adult cells can be
reset to an embryonic state [2,3]. Using this strategy,
researchers have generated cloned embryos that possess
the potential to develop into an adult animal or become
an embryonic stem cell (ESC) line that is genetically
identical to that of the donor nucleus [4,5]. These
experiments established that no irreversible changes are
made to the genome during development and further
showed that animal oocytes harbored factors that could
accomplish nuclear reprogramming.
In a related series of experiments, a number of
researchers have shown that when somatic cells are
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silence the expression of somatic genes and establish a
program of transcription indistinguishable from ESCs,
indicating that ESCs contain the necessary reprogram-
ming activities to accomplish this transformation [6,7].
Thus, the cytoplasm of the enucleated oocyte and the
ESC is able to re-establish the pluripotent state via a
mechanism dependent on global epigenetic and tran-
scriptional changes.
The mechanism by which this transformation occurred
and the mediators of nuclear reprogramming were
largely undefined. In a breakthrough experiment, Taka-
hashi and Yamanaka [8] identified four factors normally
found in ESCs–Oct3/4, Sox2, Klf4, and c-Myc (OSKM)–
closely resemble mouse ESCs. They called these iPS cells.
Since this first report, the technique has been rapidly
confirmed, improved, and subsequently applied to
successfully reprogram somatic cells. This technology
has since given birth to an entire field that has grown at a
phenomenal pace.
Major recent advances
The rate at which iPS lines are being created is rapidly
increasing. Although most iPS cells have been created
from fibroblasts, in the past two years lines have also
been created from adult neural stem cells [9], keratino-
cytes [10], hematopoietic somatic cells [11-13], fetal cells
harvested during both amniotic fluid and chorionic
villus sampling, and several other somatic cell types [11].
It appears that reprogramming is possible in almost any
cell type, although the efficiency of the reprogramming
process varies between cell types. Finding the best
somatic cell types to accomplish reprogramming remains
a main challenge for iPS cell research; we will discuss this
in greater detail later on. Significant progress has been
made in the next natural step after iPS cell creation: re-
differentiating iPS cells into somatic cells. iPS cells have
been re-differentiated into several somatic tissues,
including active motor neurons [14], insulin-secreting
islet-like clusters [15], and a number of cardiovascular
cells (arterial endothelium, venous endothelium, lym-
phatic endothelium, and cardiomyocytes) [16,17].
Disease modeling with iPS cells
Currently, there are two major questions addressed by
iPS cell research. One seeks to produce iPS cell lines that
capture the genotypes of disease. These cell lines would
offer an unprecedented opportunity to understand
pathobiology, identify abnormalities in the develop-
ment or function of differentiated cells affected by
disease, develop therapies that render these cells resistant
to disease, and provide sources of material for cell
replacement therapy. Ultimately, the goal is to develop
new therapies in which treatment is either non-existent
or insufficient.
Numerous groups have reported the creation of disease-
specific iPS lines. A group headed by Kevin Eggan [18]
has generated iPS cells from patient fibroblasts of a
familial form of amyotrophic lateral sclerosis. Another
group, headed by George Daley [19], has produced iPS
cells from patients with 10 different genetic diseases,
including Parkinson’s disease, type-1 diabetes, Duch-
enne and Becker muscular dystrophy, adenosine
deaminase deficiency-related severe combined immuno-
deficiency, Shwachman-Bodian-Diamond syndrome,
Gaucher’s disease type III, Huntington’sd i s e a s e ,
Down’s syndrome, and the carrier state of Lesch-Nyhan
syndrome. Groups led by Svendsen [20] and Jaenisch
[21] have added to the list of disease-specific iPS cells by
creating human cell-based models of spinal muscular
atrophy and Parkinson’s disease, respectively.
More recently, the Kan group [11] created iPS cells from
skin fibroblasts of a patient with homozygous beta-
thalassemia and subsequently differentiated them into
hemoglobin-producing hematopoietic cells. In theory,
these cells could be treated with gene therapy to yield
autologous hematopoietic cells that function normally.
The Belmonte group [22] advanced this goal when they
derived iPS cells from dermal fibroblasts harvested from
Fanconi anemia patients, corrected the genetic defect
using lentiviral vectors encoding for FANCA and
FANCD2, and subsequently derived somatic cells that
were phenotypically disease-free.
In a publication demonstrating the broad utility of
disease-specific iPS cells, the Studer group [23] generated
iPS cells from patients with familial dysautonomia (FD),
re-differentiated the iPS cells into cells of all three germ
layers, and demonstrated tissue-specific mis-splicing of
the protein responsible for FD. During redifferentiation,
they also gained novel insights into the pathogenesis of
FD: they demonstrated a possible mechanism for the
tissue specificity of FD and uncovered defects in cell
differentiation and migration. Lastly, they successfully
used their in vitro model to screen candidate drugs.
Mechanistic understanding
The second major question in iPS cell research seeks to
define the underlying mechanism by which nuclear
reprogramming is accomplished. This includes identify-
ing the molecular players, the key cellular and molecular
events, and the likely ways in which this process might
fail. The goal is to make the iPS induction process safer
and more efficient and to one day manipulate the
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that were sufficient to reprogram mouse somatic cells tounderlying cellular state of any cell, thereby generating
specific cell types at will.
The nature of the factors required for the reprogramming
of somatic cells into iPS cells has been elucidated. In
particular, Oct4 has emerged as a central molecule in iPS
cell reprogramming; for example, neural stem cells can
be reprogrammed to iPS cells with Oct4 alone, which
was not unexpected as they express high levels of
endogenous Sox2 [9]. To date, no cell line has been
reprogrammed without Oct4. While Yamanaka’s original
four-factor combination remains the most widely used,
several other combinations have been shown to generate
iPS cells. Two of the earliest alternative combinations
were developed by the Thompson group [24]. They
successfully used Oct4/Sox2/Nanog/Klf4 as well as
as Oct4/Sox2/Nanog/Lin28 to create iPS cell lines.
Recently, the Ng group [25] was able to reprogram
mouse embryonic fibroblasts (MEFs) by using Esrrb,
which is an orphan nuclear receptor, in combination
with Oct4, Sox2, and c-Myc.
It has also been shown that some of the reprogramming
factorscan be replaced with chemicals. The Melton group
[26] added valproic acid to newborn human skin
(fibroblast) cells in culture and was able to create iPS
cells with only two reprogramming factors, Oct4 and
Sox2, eliminating the need for two potent cancer-
promoting genes, c-Myc and Klf4. The Ding group [27]
used a combination of the small molecules BIX-01294
and BayK8644 to generate iPS from MEFs that were
transfected with only Oct4 and Klf4. The promise of
these approaches is to create iPS cells by using chemicals
alone.
Improving induction
Several groups have recently developed several alter-
native iPS cell production methods. The iPS cells
produced in each new method appear to be very similar
to those produced in the traditional method. Each new
method has its own advantages and disadvantages as
compared with the original method, and each provides
insight into how scientists may be able to develop iPS
cells that are safe for use in clinical trials.
Hochedlinger and colleagues [28] used adenoviruses to
deliver reprogramming factors into adult mouse liver
cells. Newborn mouse fibroblasts were also transduced;
however, these were transgenic and required doxycycline
induction of Oct4 expression for iPS generation. Very
recently, the Freed group [29] established three human
iPS lines from fibroblasts by using adenoviruses. The
adenoviral approach is advantageous because it avoids
integrating exogenous genes into the genome and the
potential for insertional mutagenesis. The virus needs to
be present for only a short time in order to accomplish
reprogramming. However, the technique is inefficient
compared with iPS transduction with retroviruses and
still uses cancer-promoting genes, and the adenovirus
may still integrate into the host DNA at low frequencies.
Yamanaka’s group [30] reported success at generating
murine iPS cells without using any viruses. They
successfully reprogrammed mouse cells by transfection
with two plasmid constructs carrying the reprogramming
factors; the first plasmid expressed c-Myc while a second,
polycistronic plasmid expressed Oct4, Klf4, and Sox2. In
a related approach, the Belmonte group [31] used one
polycistronic construct expressing all four factors to
achieve nucleofection in MEFs and induced iPS forma-
tion. These methods avoid viruses entirely but still
require cancer-promoting genes to accomplish repro-
gramming. As with the adenoviral strategies, plasmid-
based approaches are much less efficient compared with
retroviral methods and begin with embryonic skin cells,
which may be more amenable to reprogramming than
adult skin cells. Moreover, transfected plasmids have
been shown to integrate into the host genome and
therefore pose a risk of insertional mutagenesis [32].
Three separate research groups addressed the low
efficiency of non-retroviral approaches to iPS induction
by using the piggyBac transposon system to deliver the
OSKM reprogramming factors to MEFs [33-35]. piggyBac
is unusual among transposon systems because upon re-
excision of the exogenous genes, no ‘footprint’ mutations
are left in the host cell genome.
The Jaenisch group [21] reprogrammed fibroblasts from
Parkinson’s disease patients by using floxed doxycycline-
inducible lentiviral vectors that can be excised using Cre
recombinase. While this strategy yielded human iPS cells
with global transcriptomes that more closely resembled
those of human ESCs, a genomic ‘footprint’ (the loxP
site) was left behind, so the mutagenicity of the retroviral
approaches remains.
The Thomson group [36] recently used the episomal
vector oriP/EBNA1 to generate iPS cells from human
foreskin fibroblasts. This vector is duplicated as an
extrachromosomal episome once per cell cycle and is
stable as long as drug selection is used. In the absence of
drug selection, the episomal vector is lost at a rate of 5%
per iPS generation. After a few generations, iPS cells that
do not carry the vector can be isolated. The major
disadvantage to this approach is its low efficiency.
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using recombinant proteins. The protein reprogramming
factors were delivered into MEFs by conjugating the
proteins to poly-arginine, a short peptide that mediates
protein transduction. A parallel approach was shown to
work in human fibroblasts by the Kim group [38], who
fused the OSKM factors to cell-penetrating peptide
sequences. The major advantage to these protein-based
strategies is that exogenous genes are not introduced.
However, the strategy is again rather inefficient.
Increasing efficiency
The efficiency of reprogramming adult fibroblasts
remains low (<0.1%). Whether this frequency reflects
the need for the precise timing, balance, and absolute
levels of expression of the reprogramming genes or
selection for rare genetic/epigenetic changes either
initially present in the somatic cell population or
acquired during prolonged culture remains unsolved.
Although considerable advances have been made in
identifying the complex networks involved, we do not
yet understand how these factors maintain pluripotency,
how growth factors control and stabilize these networks,
or how these cells respond so precisely to differentiation
cues. Certain small molecules, including valproic acid (a
histone deacetylase inhibitor) [39], 5-aza-cytidine [40],
and BIX01294 [41], seem to improve the efficiency of the
iPS cell generation process. We expect that more
chemicals that improve the efficiency of iPS cell
reprogramming will be identified. Ultimately, the goal
is to develop a cocktail of reprogramming factors which
efficiently and reliably transduces somatic cells to iPS
cells.
Most recently, attention has focused on p53 as a key
player in the efficiency of iPS cell transduction. In 2008,
the Deng group [42] demonstrated that adding p53
siRNA (small interfering RNA) to the OSKM reprogram-
ming factors increased the rate of iPS cell colony
formation by up to 100-fold. However, many of the
resulting iPS cells were only partially reprogrammed, and
none yielded teratomas in vivo.
The central role of p53 in controlling iPS cell transduc-
tion has been better defined in several newly published
papers. The Yamanaka group [43] showed that in
homozygous p53 knockout MEFs, 10% of the cells
could be transduced to iPS cells with three reprogram-
ming factors (Oct4/Sox2/Klf4). They further showed that
terminally differentiated, p53 null T cells could be turned
into iPS cells. The Belmonte group [44] arrived at similar
conclusions when they infected cells with p53 shRNA
(small hairpin RNA) and when they transduced p53
+/−
and p53
−/− MEFs into iPS cells. They further showed that
reducing p21 and Bax levels, two factors downstream of
p53, also increased the efficiency of iPS cell transduction.
Two separate groups, led by Serrano [45] and Hoche-
dlinger [46], focused on the Ink4/Arf locus, which is
responsible for inhibiting Mdm2, which in turn is the
main destabilizing enzyme of p53. The Serrano group
found that downregulating tumor suppressors contained
in the Ink4/Arf locus increased the efficiency of iPS cell
transduction. The Hochedlinger group showed that cells
with low endogenous Ink4a/Arf locus products are more
readily reprogrammed into iPS cells and that genetic
ablation of p53 converts non-reprogrammable somatic
cells into cells that could be transduced to iPS cells.
Lastly, the Blasco group [47] showed that p53 is
responsible for preventing iPS cell transduction of G3
Terc
−/− MEFs, which are cells with short telomeres. Taken
together, these data show that the molecular network
surrounding p53 strongly inhibits iPS cell transduction
and that the disruption of this network increases the
efficiency of iPS cell generation many-fold.
While the precise molecular mechanisms behind p53
inhibition of iPS cell reprogramming are unknown, a
newly published study suggests that the very process of
reprogramming upregulates tumor suppressor expres-
sion. The Gil group [48] found that the OSKM
reprogramming factors induced DNA damage and
chromatin remodeling, thereby resulting in the develop-
ment of senescence characteristics, including expression
of p16, p21, and p53.
More animal models
The creation of iPS lines from cells of species other than
humans or mice expands the research potential of iPS in
additional animal models. The Deng group [49]
generated iPS cells from adult rhesus monkey fibroblasts.
Two separate groups, one led by Ding [50] and the other
by Xiao [51], created iPS cells from adult rat cells.
Most recently, iPS cells have been derived from somatic
pig cells. The Xiao group [52] used tetracycline-inducible
human Oct4/Sox2/Klf4/c-Myc/Nanog/Lin28 delivered
via lentiviruses to transduce primary pig ear fibroblasts
and primary bone marrow cells into iPS cells. The
Roberts group [53] transduced porcine fetal fibroblasts
into iPS cells by using human OSKM delivered with
lentiviruses. The availability of model animal iPS cells
offers a new and potentially powerful model for
therapeutics.
Complete pluripotency
Previously, iPS cells had not been shown to contribute
fully to all of the cell types in adult organisms. In a
significant breakthrough, three separate groups (led by
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reported that, in mice, MEF-derived iPS cells could be
injected into tetraploid blastocysts and result in the live
birth of mice derived entirely from iPS cells. Different iPS
lines were, to varying degrees, effective at producing
viable offspring, with some lines showing early termina-
tion of fetal development. The success of this approach
seems related to the age of the somatic cells from which
the iPS cells were derived. With these reports, the debate
over the equivalence of ESCs and iPS with regard to
pluripotency has been resolved, at least in mice.
Future directions
In the rapidly developing field of iPS cell research, we
expect to see improved and more efficient iPS derivation
protocols in the near future. The key will be the
development of methods that do not rely on the
integration of the transgenes but that are still highly
efficient. As shown by the recent tetraploid complemen-
tation studies, the age at which somatic cells are
harvested plays a key role in the derived iPS cells’
pluripotency. As such, it will be important to identify
somatic cell types that are easily harvested and that
harbor the fewest mutations. It might be advisable to
collect cord blood from newborns as they have been
shown to be candidates for reprogramming and would at
that time harbor very few mutations.
We are only beginning to understand the mechanism
and kinetics of iPS cell reprogramming. Elucidation of
these would overcome the current problems of low
frequency and inefficient iPS cell transduction. An
integrative genomic analysis of the reprogramming
process demonstrated that the repression of lineage-
specific transcription factors and DNA de-methylation
are critical and inefficient steps [40].
Several reviews have addressed the question of quality
standards for iPS cells [57,58]. A minimum set of criteria
for iPS characterization includes: (a) pluripotent stem
cell morphology and unlimited self-renewal, (b) expres-
sion of pluripotency markers and downregulation of
differentiation markers, (c) reprogramming factor inde-
pendence, and (d) ‘proof of functional differentiation
through the highest-stringency test acceptable’ [58].
The promise of iPS cells includes applications in both
patient care and advanced cellular research. Currently,
incompletesilencingofviraltransgenesandevencontinued
dependenceonexogenousfactorstomaintainpluripotency
are barriers to fulfilling the promise of iPS cells.
It has also been shown that significant differences in the
differentiation potential of different human ESC lines
exist, even though the observable differences in the
pluripotent state are marginal [59]. Thus, although the
demonstration of complete iPS cell pluripotency via
the tetraploid complementation studies was significant,
it remains necessary to develop and standardize differ-
entiation protocols that assess the potential of iPS lines.
While the transcriptional and genomic characterizations
of iPS cells are somewhat established, no proteomic
characterization has been performed. The recent dis-
covery of microRNAs (miRNAs) presents another area of
potential research and characterization; the Wu group
[60] at Stanford University performed the first ‘miRNA-
ome’ analysis of human iPS cells compared with human
ESCs and fibroblasts.
Conclusions
In a short period of time, iPS cells have proven to be a
major new frontier for biologic research. iPS cells have
been created in humans and several animal models,
including mice, rats, pigs, and primates. They have been
generated from numerous somatic cell types, and
disease-specific iPS cells have been created from dozens
of diseases. Most recently, iPS cells have been shown to
autonomously develop into full-term mice via tetraploid
complementation. Over the coming months and years,
improved iPS cell generation efficiency and iPS cell-
based disease modeling and drug discovery will yield
new discoveries, culminating in the development of
low-cost, patient-specific, cell-based therapies.
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